exatecan

Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL).Exatecan has antitumor activity and may be used in cancer research.

(4-NH2)-Exatecan is a topoisomerase inhibitor with potential anticancer activity for the synthesis of antibody drug conjugates (ADCs).

Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA) is a derivative of Exatecan and serves as an anticancer agent. It exhibits significant antitumor activity and can be utilized in research related to cancer, such as solid tumors.

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) consists of a cytotoxin, the topoisomerase I inhibitor DX-8951, and a linker sensitive to cathepsin, forming a drug-linker conjugate for antibody-drug conjugates (ADCs).

Glycyl-Exatecan (Glycyl-DX-8951) is the active metabolite released from DE-310 through enzymatic cleavage of the spacer. It exhibits antitumor activity in vivo and can be used in research on solid tumors.

Exatecan Mesylate (DX8951f) is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).

Dxd (OQM5SD32BQ) is a potent DNA topoisomerase I inhibitor (IC50= 0.31 μM). Dxd was used as a conjugate drug for HER2-targeted ADCs.

MC-GGFG-DX8951 (MC-GGFG-Exatecan) is an antibody-coupled drug (ADC) drug-linker conjugate (DLC) consisting of DX8951, a potent DNA topoisomerase I inhibitor, the linker MC, and the cleavable peptide chain GGFG, and has antitumor potential.

APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker conjugate utilized in the synthesis of antibody-drug conjugates (ADCs), comprising Exatecan (ADC payload) and a linker within its structure.

DBCO-PEG3-VC-Exatecan (compound 25) is a Drug-Linker Conjugate for ADC (ADC Drug-Linker Conjugate), consisting of the ADC linker (DBCO-PEG3-VC) coupled with the DNA topoisomerase I (topoisomeraseI) inhibitor Exatecan. This conjugate is utilized in the development of antibody-drug conjugates for targeted cancer therapy.

Compound 94 (MC-GGFG-PAB-Exatecan) is an ADC drug-linker conjugate utilized in the synthesis of antibody-drug conjugates (ADCs).

Val-Ala-PABC-N(Mesylpropane)-Exatecan is a drug-linker conjugate (Drug-Linker Conjugates for ADC) composed of a cleavable Val-Ala-PABC-N(Mesylpropane) linker and Exatecan, a topoisomerase I inhibitor.

GGFG-PAB-Exatecan TFA consists of the toxin molecule Exatecan and the linker GGFG-PAB, and it serves as a drug-linker conjugate for synthesizing ADC molecules.

2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a drug-linker conjugate used in ADC (antibody-drug conjugate) applications. It consists of a linker and Exatecan.

C-lock-GGFG-Exatecan is a thiol-reactive drug linker. GGFG is a peptidase-activatable peptide. After entering the lesion, it can enable the release and activation of the payload Exatecan. C-lock-GGFG-Exatecan is commonly used in the synthesis of antibody-drug conjugates (ADCs).

MC-PEG2-VA-PAB-Exatecan (Compound DL-18) is a drug-linker conjugate designed for use in antibody-drug conjugates (ADC). It consists of Exatecan and a linker. This compound is utilized in the synthesis of ADCs.

Mal((3S,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diamine-PEG12)-β-Glu-PAB-Exatecan (LP1) is a drug-linker conjugate used for ADCs (antibody-drug conjugates). It comprises a potent DNA topoisomerase I inhibitor, Exatecan, and the linker Mal((3S,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diamine-PEG12)-β-Glu-PAB, for the synthesis of the ADC AZD0516.

P5(PEG12)-VC-PAB-Exatecan (LP3) is an integral part of a drug-linker conjugate for ADC, formed by linking P5(PEG24)-VC-PAB with the DNA topoisomerase I inhibitor, Exatecan. It is utilized in the preparation of antibody-drug conjugates (ADC) and employed in tumor research.

Mc-PEG4-Val-Ala-PAB-Exatecan is a drug-linker conjugate used in ADC (antibody-drug conjugate) formulations. This compound comprises an ADC linker component (Mc-PEG4-Val-Ala-PAB) and the DNA topoisomerase I inhibitor, Exatecan.

β-Glu-PAB(CH2NH2)-Exatecan (Compound 9a) is an inhibitor of topoisomerase I. It binds to the topoisomerase I-DNA complex, preventing the re-ligation of DNA strands, leading to DNA breaks and apoptosis. In the tumor microenvironment, where β-glucuronidase is highly expressed, β-Glu-PAB(CH2NH2)-Exatecan is specifically cleaved to release Exatecan, which then exerts its cytotoxic effects. Additionally, β-Glu-PAB(CH2NH2)-Exatecan serves as an intermediate for the synthesis of Mal((3S,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diamine-PEG12)-β-Glu-PAB-Exatecan. This compound holds potential for cancer research.

Exatecanintermediate 8 serves as an intermediate in the synthesis of Exatecan. Exatecan (DX-8951) is a commonly used cytotoxin component in ADC (Antibody-Drug Conjugate) preparation, and it functions as an inhibitor of DNA topoisomerase I (IC50=2.2 μM).

Exatecanintermediate 10 serves as an intermediate in synthesizing Exatecan. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), utilized for cancer research.

Exatecan Intermediate 3 is an intermediate of Exatecan. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), and it is utilized in cancer research. Exatecan Intermediate 3 can be employed in the synthesis of Antibody-Drug Conjugates (ADCs).

Exatecanintermediate 11 is an intermediate compound used in the synthesis of Exatecan. Exatecan (DX-8951) is a frequently utilized cytotoxic component in the preparation of antibody-drug conjugates (ADC Cytotoxin) and serves as an inhibitor of DNA topoisomerase I (topoisomeraseI) with an IC50 of 2.2 μM.